	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
MULTIPLE MYELOMA (MM)					
Lenalidomide	Relapsed/refractory				
	Newly diagnosed				
	Maintenance				
Pomalidomide	Relapsed/refractory				
Thalidomide	Newly diagnosed				
PD-L1 Inhibitor: durvalumab[a]					
CC-122					
BCMA CAR-T (bb2121)[b]					
CC-220	Relapsed/refractory				
Citarinostat (ACY-241)	Relapsed/refractory				
MYELODYSPLASTIC SYNDROMES (MDS)					
Azacitidine for injection					
Lenalidomide	Deletion 5q				
CC-486	Lower-risk				
	Post hypomethylating agent (HMA) failure				
Luspatercept (ACE-536)[c]					
PD-L1 Inhibitor: durvalumab[a]					
Anti-CD47 Antibody: CC-90002					
ACUTE MYELOID LEUKEMIA (AML)					
Azacitidine for injection	AML (20%-30% blasts) (EU)				
	AML (>30% blasts) (EU)				
CC-486	Post-induction AML maintenance				
IDH2 Inhibitor: enasidenib (AG-221)[d]				Regulatory Submission*	
Pan-IDH Inhibitor: AG-881[d]					
PD-L1 Inhibitor: durvalumab[a]					
Anti-CD47 Antibody: CC-90002					
CC-90009					

[a]In collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC. AstraZeneca MedImmune [b]In collaboration with bluebird bio, Inc. bluebirdbio
[c]In collaboration with Acceleron Pharma, Inc. ACCELERON [d]In collaboration with Agios Pharmaceuticals, Inc. agios

Celgene

*'Regulatory submission' indicates US and/or EU submission unless other country/region is indicated under Area of Research.

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

© 2017 Celgene Corporation 04/17

	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
LYMPHOMA					
Lenalidomide	Mantle cell lymphoma: Relapsed/refractory (US)	■	■	■	■
	Mantle cell lymphoma: Relapsed/refractory (EU)	■	■	■	■
	Diffuse large B-cell lymphoma (ABC subtype): First-line	■	■	■	
	Indolent lymphoma: Relapsed/refractory	■	■	■	
	Follicular lymphoma: First-line	■	■	■	
	Adult T-cell leukemia-lymphoma (Japan)	■	■	■	■
Romidepsin for injection	Cutaneous T-cell lymphoma (US)[a]	■	■	■	■
	Peripheral T-cell lymphoma: Relapsed/refractory (US)[a]	■	■	■	■
	Peripheral T-cell lymphoma: Relapsed/refractory (Japan)	■	■		
	Peripheral T-cell lymphoma: First-line	■	■	■	
CC-122	Diffuse large B-cell lymphoma[a]	■			
	Indolent lymphoma: Relapsed/refractory	■			
CC-486		■			
PD-L1 Inhibitor: durvalumab[b]	Non-Hodgkin lymphoma (NHL)	■			
CD19 CAR-T (JCAR017)[c]	Aggressive large B-cell lymphoma: Relapsed/refractory	■			
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)					
CC-122		■			
PD-L1 Inhibitor: durvalumab[b]		■			
BETA-THALASSEMIA					
Luspatercept (ACE-536)[d]		■	■	■	

[a]Filing for regulatory approval based on pivotal phase II data. [b]In collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC. AstraZeneca MedImmune

[c]In collaboration with Juno Therapeutics. Juno Therapeutics Celgene has commercial rights outside of North America and China.

[d]In collaboration with Acceleron Pharma, Inc. ACCELERON

Celgene

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

© 2017 Celgene Corporation 04/17

SOLID TUMORS

	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
Paclitaxel protein-bound particles for injectable suspension (albumin-bound) (US)/paclitaxel formulated as albumin-bound nanoparticles (EU)	Breast: Metastatic	■	■	■	■
	Non-small cell lung: Advanced (first-line)	■	■	■	■
	Pancreatic: Metastatic (first-line)	■	■	■	■
	Pancreatic: Adjuvant	■	■	■	
	Gastric: Metastatic (Japan)[a]	■	■	■	■
CC-486	Breast: Metastatic	■	■		
	Non-small cell lung: Advanced	■	■		
Marizomib	Glioblastoma	■	■		
CC-122	Hepatocellular carcinoma	■			
Anti-CD47 Antibody: CC-90002		■			
Pan-IDH Inhibitor: AG-881[b]	Glioma	■			
LSD1 Inhibitor: CC-90011		■			

[a]Trial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd. [b]In collaboration with Agios Pharmaceuticals, Inc. agios

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

© 2017 Celgene Corporation 04/17

	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
INFLAMMATION & IMMUNOLOGY					
Apremilast	Psoriatic arthritis (PSA)	■	■	■	■
	Psoriasis	■	■	■	■
	Ankylosing spondylitis	■	■	■	
	Behçet's disease	■	■	■	
	Ulcerative colitis	■	■		
Mongersen (GED-0301)	Crohn's disease	■	■	■	
	Ulcerative colitis	■	■		
Ozanimod	Relapsing multiple sclerosis	■	■	■	
	Ulcerative colitis	■	■	■	
	Crohn's disease	■	■		
RPC4046[a]	Eosinophilic esophagitis	■	■		
CC-220	Systemic lupus erythematosus	■	■		
CC-90001	Fibrosis	■			
CC-90006	Autoimmune disorders	■			
CELLULAR THERAPIES					
PDA-002	Diabetic foot ulcers	■	■		
	Diabetic peripheral neuropathy	■	■		
PNK-007	AML	■			
	MM	■			

[a]Under co-development option with AbbVie.

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

© 2017 Celgene Corporation 04/17